Insights / Whitepapers

Tokenized data: the power to deliver robust patient insights for a complex real world

Written by Shea O’Connell, Viktor Chirikov, Xiaocong Li, Hannah Matthews and Michael Chance on Wednesday, November 5, 2025

In today’s pharmaceutical market, stakeholders demand that new therapies reach patients faster and at lower cost. But the process of introducing new therapies increasingly presents challenges to both these aims.

Health technology assessment (HTA) bodies routinely demand real-world evidence (RWE) to support reimbursement decisions for new therapies under consideration. Yet patient treatment journeys are becoming more complex and difficult to model for evidence generation, often including primary, secondary, and multidisciplinary care, each with different providers and separate data systems.

In this whitepaper, OPEN Health’s RWE experts introduce the concept of tokenized real-world data (RWD) and demonstrate how it can be used to overcome these challenges.

The paper includes two examples from their experience of using tokenized RWD in the US and UK as part of an integrated evidence generation plan.

We have reserved you a copy of this whitepaper. Please fill in your details to download it now.

OPEN Health authors – RWE and Market Access Experts:

At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.

By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across Medical Affairs and market access unlocks faster, smarter routes to market.

OPEN Health. The right combination to unlock possibilities.

For information about OPEN Health’s services and how we could support you, please get in touch.

Accept functional cookies to download the whitepaper

We are excited to share our latest thinking with you. Please fill out the form to download the whitepaper.

"*" indicates required fields

Download Whitepaper

Something went wrong. Please try again.